LANEBURY GROWTH CAP. (L01) - Net Assets
Based on the latest financial reports, LANEBURY GROWTH CAP. (L01) has net assets worth €452.04K EUR (≈ $528.48K USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€8.03 Million ≈ $9.39 Million USD) and total liabilities (€7.58 Million ≈ $8.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check L01 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €452.04K |
| % of Total Assets | 5.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.3 |
LANEBURY GROWTH CAP. - Net Assets Trend (2022–2025)
This chart illustrates how LANEBURY GROWTH CAP.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see LANEBURY GROWTH CAP. (L01) market capitalisation.
Annual Net Assets for LANEBURY GROWTH CAP. (2022–2025)
The table below shows the annual net assets of LANEBURY GROWTH CAP. from 2022 to 2025. Also explore L01 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €-527.96K ≈ $-617.24K |
-139.59% |
| 2024-06-30 | €1.33 Million ≈ $1.56 Million |
-40.77% |
| 2023-06-30 | €2.25 Million ≈ $2.63 Million |
-46.48% |
| 2022-06-30 | €4.21 Million ≈ $4.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LANEBURY GROWTH CAP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 517021500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €5.77 Million | % |
| Total Equity | €-527.96K | 100.00% |
LANEBURY GROWTH CAP. Competitors by Market Cap
The table below lists competitors of LANEBURY GROWTH CAP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kukbo Co. Ltd.
KO:001140
|
$150.40K |
|
Meyer Burger Tech AG
SW:MBTN
|
$151.86K |
|
First Class Metals PLC
LSE:FCM
|
$152.29K |
|
Cirata plc
LSE:CRTA
|
$152.42K |
|
Fusion Antibodies PLC
LSE:FAB
|
$148.66K |
|
Vergnet
PA:ALVER
|
$147.53K |
|
Braime Group PLC
LSE:BMT
|
$146.01K |
|
Maintel Holdings Plc
LSE:MAI
|
$145.86K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LANEBURY GROWTH CAP.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,333,682 to -527,962, a change of -1,861,644 (-139.6%).
- Net loss of 1,939,478 reduced equity.
- Other factors increased equity by 77,834.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.94 Million | -367.35% |
| Other Changes | €77.83K | +14.74% |
| Total Change | €- | -139.59% |
Book Value vs Market Value Analysis
This analysis compares LANEBURY GROWTH CAP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €0.41 | €0.04 | x |
| 2023-06-30 | €0.22 | €0.04 | x |
| 2024-06-30 | €0.13 | €0.04 | x |
| 2025-06-30 | €-0.05 | €0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LANEBURY GROWTH CAP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-43.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.90% | 0.00% | 0.00x | 1.20x | €-383.00K |
| 2023 | -99.81% | 0.00% | 0.00x | 3.20x | €-2.47 Million |
| 2024 | -73.73% | 0.00% | 0.00x | 5.32x | €-1.12 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.89 Million |
Industry Comparison
This section compares LANEBURY GROWTH CAP.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LANEBURY GROWTH CAP. (L01) | €452.04K | 0.90% | 16.77x | $148.96K |
| Covestro AG (1COV) | $5.38 Billion | 33.92% | 1.06x | $11.10 Billion |
| CENTESSA PHARMACEUTICALS (260) | $236.24 Million | -63.95% | 0.52x | $5.35 Billion |
| 2invest AG (2INV) | $63.16 Million | 2.50% | 0.02x | $70.69 Million |
| COINSHARES I. LS-000247 (3TW) | $393.95 Million | 33.24% | 14.29x | $472.53 Million |
| Adaptimmune Therapeutics plc (473A) | $166.14 Million | -43.08% | 0.41x | $42.94 Million |
| KINGMAN MINERALS LTD. (47A) | $1.17 Million | -63.86% | 0.49x | $275.68K |
| GENOR BIOPHARMA DL-00002 (67N0) | $1.15 Billion | -4.45% | 0.12x | $93.97 Million |
| BENO Holding AG (BENH) | $25.95 Million | 20.74% | 2.63x | $72.90K |
| Biotest Aktiengesellschaft (BIO) | $476.90 Million | -0.99% | 1.32x | $976.15 Million |
| Biotest Aktiengesellschaft (BIO3) | $371.10 Million | -8.54% | 2.24x | $656.94 Million |
About LANEBURY GROWTH CAP.
Lanebury Growth Capital Ltd. is a venture capital firm specializing in early stage. Lanebury Growth Capital Ltd. was founded in 2011 and is headquartered in Vancouver, Canada.